Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, a… Read more
Dermapharm Holding SE (DMPHF) - Total Assets
Latest total assets as of September 2025: $2.12 Billion USD
Based on the latest financial reports, Dermapharm Holding SE (DMPHF) holds total assets worth $2.12 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dermapharm Holding SE - Total Assets Trend (2013–2024)
This chart illustrates how Dermapharm Holding SE’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Dermapharm Holding SE - Asset Composition Analysis
Current Asset Composition (December 2024)
Dermapharm Holding SE's total assets of $2.12 Billion consist of 28.5% current assets and 71.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.8% |
| Accounts Receivable | $105.00 Million | 5.1% |
| Inventory | $339.86 Million | 16.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $512.31 Million | 24.6% |
| Goodwill | $576.38 Million | 27.7% |
Asset Composition Trend (2013–2024)
This chart illustrates how Dermapharm Holding SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dermapharm Holding SE's current assets represent 28.5% of total assets in 2024, a decrease from 52.0% in 2013.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2024, up from 1.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 27.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 27.7% of total assets.
Dermapharm Holding SE Competitors by Total Assets
Key competitors of Dermapharm Holding SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Dermapharm Holding SE - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Dermapharm Holding SE generates 0.57x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Dermapharm Holding SE generates $5.47 in net profit.
Dermapharm Holding SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.20 | 1.66 | 3.01 |
| Quick Ratio | 1.04 | 0.74 | 1.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $351.49 Million | $ 248.17 Million | $ 267.18 Million |
Dermapharm Holding SE - Advanced Valuation Insights
This section examines the relationship between Dermapharm Holding SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.90 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -3.7% |
| Total Assets | $2.08 Billion |
| Market Capitalization | $310.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dermapharm Holding SE's assets below their book value (0.15 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Dermapharm Holding SE's assets decreased by 3.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Dermapharm Holding SE (2013–2024)
The table below shows the annual total assets of Dermapharm Holding SE from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.08 Billion | -3.73% |
| 2023-12-31 | $2.16 Billion | +52.93% |
| 2022-12-31 | $1.41 Billion | +0.42% |
| 2021-12-31 | $1.41 Billion | +14.91% |
| 2020-12-31 | $1.22 Billion | +17.18% |
| 2019-12-31 | $1.04 Billion | +48.30% |
| 2018-12-31 | $704.58 Million | +69.65% |
| 2017-12-31 | $415.30 Million | +33.24% |
| 2016-12-31 | $311.70 Million | +5.07% |
| 2015-12-31 | $296.67 Million | -10.26% |
| 2014-12-31 | $330.60 Million | -5.54% |
| 2013-12-31 | $349.98 Million | -- |